|Bid||0.00 x 4000|
|Ask||0.00 x 1100|
|Day's Range||16.04 - 16.82|
|52 Week Range||13.42 - 32.20|
|Beta (3Y Monthly)||2.91|
|PE Ratio (TTM)||16.15|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.56|
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Exelixis, Inc. (EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. The company discovered its three commercially available products, CABOMETYX®(cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib) and have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. The company announced that Michael M. Morrissey, Ph.D., the company's President, and Chief Executive Officer, will provide an overview of the company at the Stifel 2018 Healthcare Conference taking place November 13-14 in New York, NY.
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
In the third quarter, Exelixis’s (EXEL) Cabozantinib franchise generated revenues of $162.9 million, reflecting ~69% YoY growth. Exelixis’s Cabometyx generated revenues of $158.3 million in the third quarter, reflecting ~75% YoY growth.
Exelixis reported revenues of $625.2 million in the first nine months of this year compared to $332.4 million in the same period the prior year. In the third quarter, Exelixis generated revenues of $162.9 million from product sales compared to $96.4 million in the third quarter of 2017, reflecting ~69% YoY growth. Exelixis generated $62.5 million in collaboration revenues in the third quarter compared to $56.1 million in the third quarter of 2017.
Exelixis (EXEL) reported net income of $126.6 million in the third quarter compared to $81.4 million in the third quarter of 2017. The company’s net income over the first nine months of this year amounted to $330.0 million compared to $115.7 million in the same period the prior year.
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / U.S. equities rolled back on Friday, ending a 3-day consecutive gain after confusing headlines about the trade talks with China. President Trump announced ...
Seeing as how several stocks are on the move due to earnings today, let’s take a look at some of the more notable ones, including that of Exelixis Inc. (NASDAQ:EXEL), Symantec Corporation (NASDAQ:SYMC), Acacia Communications Inc. (NASDAQ:ACIA), Universal Display Corporation (NASDAQ:OLED), and Weight Watchers International Inc (NASDAQ:WTW). For those of you interested in potentially partly diversifying your portfolio with hedge […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Gritstone Oncology Inc (NASDAQ: GRTS ) Repligen Corporation ...
On a per-share basis, the Alameda, California-based company said it had profit of 41 cents. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
NEW YORK, NY / ACCESSWIRE / October 31, 2018 / U.S. markets rebounded on Tuesday as trade tensions eased after President Trump hinted that the U.S. was prepared to negotiate a trade deal with China. During ...
NEW YORK, NY / ACCESSWIRE / October 26, 2018 / U.S. equities bounced back on Thursday supported mostly by gains in consumer discretionary and technology shares. The Dow Jones Industrial Average jumped ...
– Combination of cabozantinib and atezolizumab is well tolerated and shows promising anti-tumor activity –
– Cabozantinib was associated with improved overall survival and progression-free survival irrespective of PD-L1 expression in CABOSUN and METEOR trials –
Exelixis, Inc. (EXEL) announced today that its third quarter 2018 financial results will be released on Thursday, November 1, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.